Emergent BioSolutions Reports Second Quarter 2024 Financial Results
06 août 2024 17h01 HE
|
Emergent BioSolutions
Second Quarter 2024 Total Revenues of $254.7 million, above the prior guidance rangeSecond Quarter 2024 Net Loss of $283.1 million and Adjusted EBITDA of $(10.1) millionUpdates FY 2024 guidance ...
Emergent BioSolutions Expands NARCAN® Nasal Spray Distribution Capabilities to Enhance Customer Delivery Experience Across the Country
06 août 2024 08h00 HE
|
Emergent BioSolutions
Customer-focused approach and continued investments in NARCAN® Nasal Spray supply-readiness efforts help ensure opioid emergency preparedness GAITHERSBURG, Md., Aug. 06, 2024 (GLOBE NEWSWIRE)...
Emergent BioSolutions Completes Sale of RSDL® (Reactive Skin Decontamination Lotion) Kit to SERB Pharmaceuticals for $75 Million
31 juil. 2024 08h53 HE
|
Emergent BioSolutions
GAITHERSBURG, Md., July 31, 2024 (GLOBE NEWSWIRE) -- Today, Emergent BioSolutions Inc. (NYSE: EBS) announced the sale of RSDL® (Reactive Skin Decontamination Lotion) kit to SERB Pharmaceuticals, a...
Emergent BioSolutions Launches Opioid Emergency Preparedness ‘Lay, Spray, Stay’ Public Education Campaign Starring Pro Football Hall of Famer Emmitt Smith
24 juil. 2024 07h30 HE
|
Emergent BioSolutions
New video and radio segments raise awareness of a potentially life-saving, three-step method that anyone can use to respond in a suspected opioid poisoning GAITHERSBURG, Md., July 24, 2024 (GLOBE...
Emergent BioSolutions to Release Second Quarter 2024 Financial Results & Conduct Conference Call on August 6, 2024
23 juil. 2024 08h27 HE
|
Emergent BioSolutions
GAITHERSBURG, Md., July 23, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Tuesday, August 6, 2024, at 5:00 pm eastern time to discuss the financial...
Emergent BioSolutions annonce la prolongation de la durée de vie du vaporisateur nasal NARCAN® au Canada
22 juil. 2024 08h00 HE
|
Emergent Biosolutions, Inc.
Le fait de porter à quatre ans la durée de vie du vaporisateur nasal NARCAN® contribue à améliorer l’accès à la naloxone dans un contexte où les communautés sont toujours aux prises avec une hausse...
Emergent BioSolutions Announces Shelf-Life Extension for NARCAN® Nasal Spray in Canada
22 juil. 2024 08h00 HE
|
Emergent BioSolutions
The extension to a four-year shelf-life helps improve naloxone access as communities continue to grapple with the growing opioid epidemic; product with the extended shelf life has officially begun...
Emergent BioSolutions Continues to Drive Improved Financial Position as Part of Multi-Year Transformation Plan
09 juil. 2024 07h30 HE
|
Emergent BioSolutions
GAITHERSBURG, Md., July 09, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today highlights several recent advancements in improving its financial health, marked by robust cash...
Update: Emergent BioSolutions Awarded $250+ Million in Contract Modifications to Supply U.S. Government with Four Critical Medical Countermeasure Products
02 juil. 2024 09h43 HE
|
Emergent BioSolutions
GAITHERSBURG, Md., July 02, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has received more than $250 million in contract modifications from the Administration...
Emergent BioSolutions Awarded $250+ Million in Contract Modifications to Supply U.S. Government with Four Critical Medical Countermeasure Products
02 juil. 2024 08h13 HE
|
Emergent BioSolutions
GAITHERSBURG, Md., July 02, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has received more than $250 million in contract modifications from the Administration...